Technical Analysis for EARS - Auris Medical Holding AG
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| See historical EARS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Bearish Engulfing | Bearish | -0.68% | |
| Upper Bollinger Band Walk | Strength | -0.68% | |
| Volume Surge | Other | -5.19% | |
| Calm After Storm | Range Contraction | -5.19% | |
| Upper Bollinger Band Walk | Strength | -5.19% | |
| Upper Bollinger Band Touch | Strength | -5.19% | |
| Calm After Storm | Range Contraction | -2.99% | |
| Upper Bollinger Band Walk | Strength | -2.99% | |
| Outside Day | Range Expansion | -2.99% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/15/2019
- Sector: Healthcare
- Industry: Biotechnology
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Biopharmaceutical Pharmaceutical Products Drug Delivery Nervous System Perception Hearing Loss Drug Delivery Devices Ear Hearing Tinnitus
Biopharmaceutical Pharmaceutical Products Drug Delivery Nervous System Perception Hearing Loss Drug Delivery Devices Ear Hearing Tinnitus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more EARS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 39.4 |
| 52 Week Low | 2.42 |
| Average Volume | 103,263 |
| 200-Day Moving Average | 5.415 |
| 50-Day Moving Average | 2.7723 |
| 20-Day Moving Average | 2.8475 |
| 10-Day Moving Average | 2.971 |
| Average True Range | 0.1642 |
| ADX | 44.12 |
| +DI | 29.1178 |
| -DI | 11.9402 |
| Chandelier Exit (Long, 3 ATRs ) | 2.7074 |
| Chandelier Exit (Short, 3 ATRs ) | 3.1126 |
| Upper Bollinger Band | 3.112 |
| Lower Bollinger Band | 2.583 |
| Percent B (%b) | 0.64 |
| BandWidth | 18.5777 |
| MACD Line | 0.0671 |
| MACD Signal Line | 0.0557 |
| MACD Histogram | 0.0113 |
| Fundamentals | Value |
|---|---|
| Market Cap | 129.44 Million |
| Num Shares | 44.3 Million |
| EPS | -0.75 |
| Price-to-Earnings (P/E) Ratio | -3.89 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 6.14 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.11 | ||||
| Resistance 3 (R3) | 3.11 | 3.04 | 3.08 | ||
| Resistance 2 (R2) | 3.04 | 2.99 | 3.04 | 3.07 | |
| Resistance 1 (R1) | 2.98 | 2.96 | 3.01 | 2.98 | 3.06 |
| Pivot Point | 2.92 | 2.92 | 2.93 | 2.92 | 2.92 |
| Support 1 (S1) | 2.85 | 2.87 | 2.89 | 2.86 | 2.78 |
| Support 2 (S2) | 2.79 | 2.84 | 2.79 | 2.77 | |
| Support 3 (S3) | 2.73 | 2.79 | 2.76 | ||
| Support 4 (S4) | 2.73 |
